In ₹ Crore except Per Share Latest Annual | BIOCON FY26 | SUNPHARMA FY26 | DRREDDY FY26 | SYNGENE FY26 | Peer Median | |
|---|---|---|---|---|---|---|
| Valuation — at last close | ||||||
| P/E | 138.65× | 38.70× | ◆ 22.63× | 48.79× | 38.70× +258% | |
| P/B | ◆ 1.73× | 5.29× | 2.49× | 3.20× | 3.20× -46% | |
| EV/EBITDA | 21.73× | 23.53× | ◆ 14.91× | 16.11× | 16.11× +35% | |
| Market Cap | ₹63,381 Cr | ₹4.44L Cr | ₹95,274 Cr | ₹15,471 Cr | ₹95,274 Cr -33% | |
| Growth | ||||||
| Revenue CAGR 3Y | ◆ 14.85% | 10.03% | 10.96% | 5.40% | 10.03% +48% | |
| Revenue CAGR 5Y | ◆ 18.96% | 11.78% | 12.09% | 11.35% | 11.78% +61% | |
| Net Income CAGR 3Y | -16.91% | ◆ 10.57% | -2.66% | -11.98% | -2.66% -536% | |
| Revenue YoY (latest Q) | 10.00% | ◆ 10.46% | -5.51% | -15.84% | -5.51% +281% | |
| Net Income YoY (latest Q) | ◆ 53.36% | 26.53% | -69.10% | -110.38% | -69.10% +177% | |
| Profitability | ||||||
| EBITDA Margin | 20.41% | ◆ 30.33% | 19.15% | 24.57% | 24.57% -17% | |
| Net Income Margin | 2.18% | ◆ 19.69% | 12.34% | 8.47% | 12.34% -82% | |
| Return on Common Equity | 1.05% | ◆ 13.69% | 10.98% | 6.54% | 10.98% -90% | |
| Return on Capital Employed | 3.02% | ◆ 17.17% | 10.62% | 8.46% | 10.62% -72% | |
| Return on Assets | 0.58% | ◆ 10.58% | 7.15% | 4.49% | 7.15% -92% | |
| Credit & Quality | ||||||
| Total Debt/Equity | 0.40× | 0.05× | 0.16× | ◆ 0.00× | 0.05× +700% | |
| Interest Coverage | 1.51× | ◆ 43.65× | 11.76× | 9.54× | 11.76× -87% | |
| Scale — latest FY | ||||||
| Revenue / Total Income | ₹16,927 Cr | ₹58,462 Cr | ₹33,700 Cr | ₹3,739 Cr | ₹33,700 Cr -50% | |
| Net Income | ₹369 Cr | ₹11,509 Cr | ₹4,158 Cr | ₹317 Cr | ₹4,158 Cr -91% | |
| Total Assets | ₹63,651 Cr | ₹1.09L Cr | ₹58,123 Cr | ₹7,055 Cr | ₹58,123 Cr +10% | |
| EPS | ₹2.82 | ₹47.8 | ₹50.41 | ₹7.87 | ₹47.8 -94% | |
| Book Value per Share | ₹225.92 | ₹349.6 | ₹457.86 | ₹120.11 | ₹349.6 -35% | |